Johnson & Johnson
-
Pfizer Expands to Multiple Myeloma With FDA Approval for New Antibody Drug
Oncology is already a big piece of Pfizer’s drug lineup. The portfolio is expanding to multiple myeloma with FDA approval of Elrexfio, a bispecific antibody that targets the cancer protein BCMA.
-
FDA Approves J&J Combo Drug for Prostate Cancers With Certain Genetic Signature
Johnson & Johnson’s Akeega is approved for treating advanced prostate cancer with a BRCA mutation. The drug, which interferes with a way cancer cells repair themselves, will compete against recently approved drugs from Pfizer and partners AstraZeneca and Merck.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
J&J Broadens Scope in Multiple Myeloma, Winning FDA Approval for New Drug
Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.
-
J&J Gets Foothold in Head & Neck Cancer With Deal for Nanobiotix’s Lead Program
Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer. A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024.
-
Bausch + Lomb Continues Deal Streak With $106M Acquisition of J&J Eye Drops
Bausch + Lomb is acquiring Johnson & Johnson’s Blink line of eye drops. The deal comes as J&J exits the consumer business while Bausch + Lomb expands its product portfolio with its second deal in as many weeks.
-
J&J Plans Phase 3 Trial to Keep Pace in the Chase for Oral Psoriasis Drugs
Johnson & Johnson’s oral psoriasis drug met the goals of a mid-stage clinical study, and the pharma giant now plans to advance the twice-daily pill to Phase 3 testing. J&J is one of several biopharmaceutical companies developing pill alternatives to biologic drugs that are injected or infused.
-
J&J Expands in Cancer, Paying $245M for Two Next-Generation Cell Therapies
Johnson & Johnson is acquiring rights to two next-generation cell therapies from Cellular Biomedicines, both potential treatments for diffuse large B-cell lymphoma. One therapy is already in the clinic while the other is on track to begin human testing this year.
-
J&J Portfolio Review Culls RSV Vaccine, Ending the Phase 3 Program
Johnson & Johnson’s pullback from RSV research thins the pack of companies aiming to develop a vaccine for the pathogen. GSK and Pfizer have vaccines under FDA review and a shot from Moderna could soon follow.
-
J&J Drug for Rare Infant Blood Disorder Achieves Main Goal of Phase 2 Test
A Johnson & Johnson drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses. Full data from the trial will be presented at a future scientific meeting.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
J&J Stops Work on HIV Vaccine After Failure in Phase 3 Clinical Trial
Johnson & Johnson is stopping clinical development of an experimental HIV vaccine after the four-shot regimen did not beat a placebo in a late-stage study. The clinical trial failure comes follows the 2021 failure of the vaccine candidate in a different study population.
-
BioPharma, Devices & Diagnostics, SYN
J&J CEO: Our R&D Infrastructure Helps Us Maintain Innovation Amid an Uncertain Economy
Johnson & Johnson’s CEO believes the company will maintain its strong reputation for innovation amid changing economic conditions because of its hefty investments in research and development. He said it’s crucial to invest both internally and externally, as some of the most innovative and lucrative opportunities come from outside companies.
-
J&J Aims to Expand in Multiple Myeloma With First Drug for Novel Target
Johnson & Johnson is seeking FDA approval of a multiple myeloma drug that could become the first one addressing a novel target called GPRC5D. Data from the Phase 1/2 study supporting the biologics license application were presented in New Orleans during the annual meeting of the American Society of Hematology.
-
J&J multiple myeloma drug gets FDA nod, bringing patients an easier dosing option
FDA approval of Tecvayli, from Johnson & Johnson subsidiary Janssen Biotech, makes it the newest therapy that treats multiple myeloma by targeting the cancer protein BCMA. Though this off-the-shelf drug offers patients a more convenient dosing option, it comes with similar complication risks as other biologics approved for this type of blood cancer.
-
ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more
Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.
-
Regulatory recap: J&J vaccine limits, full Enhertu approval, a Vertex hold & more
The FDA amended emergency authorization of Johnson & Johnson’s Covid-19 vaccine. In other regulatory news this past week, drug approvals include a cancer drug that converted its accelerated regulatory approval to a full regulatory nod, while several companies dealt with rejections or clinical trial setbacks.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
